ReviewCancer metastasis reviews2009
Biology of urothelial tumorigenesis: insights from genetically engineered mice.
Review in Cancer metastasis reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 55 citations in OpenAlex.
- Trial
- JUNB and JUND in Urological Cancers: A Literature Review.Current issues in molecular biology · 2025Review
- Development, regeneration and tumorigenesis of the urothelium.Development (Cambridge, England) · 2022Review
- PKM2 Is Essential for Bladder Cancer Growth and Maintenance.Cancer research · 2022Article
- The Origin and Evolution of Bladder Cancer Stem Cells.Frontiers in cell and developmental biology · 2022Review
- Dominant role of CDKN2B/p15INK4B of 9p21.3 tumor suppressor hub in inhibition of cell-cycle and glycolysis.Nature communications · 2021Article
- The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.Translational cancer research · 2020Review
- Mouse and human urothelial cancer organoids: A tool for bladder cancer research.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Carcinogen-induced bladder cancer in the FVB mouse strain is associated with glandular differentiation and increased Cd274/Pdl-1 expression.American journal of clinical and experimental urology · 2019Article
- Uroplakins play conserved roles in egg fertilization and acquired additional urothelial functions during mammalian divergence.Molecular biology of the cell · 2018Article
- Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention.Molecular nutrition & food research · 2018Review
- Article
- Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium.Bladder cancer (Amsterdam, Netherlands) · 2017Article
- Inhibition of cholesterol metabolism underlies synergy between mTOR pathway inhibition and chloroquine in bladder cancer cells.Oncogene · 2016Article
- Metabolic Pathway Signatures Associated with Urinary Metabolite Biomarkers Differentiate Bladder Cancer Patients from Healthy Controls.Yonsei medical journal · 2016Article
- Role of isoenzyme M2 of pyruvate kinase in urothelial tumorigenesis.Oncotarget · 2016Article
- Article
- Article
- Animal models for bladder cancer: The model establishment and evaluation (Review).Oncology letters · 2015Article
- Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall's plaques.Urolithiasis · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Urothelium, one of the slowest cycling epithelia in the body, embodies a unique biological context for cellular transformation. Introduction of oncogenes into or removing tumor suppressor genes from the urothelial cells or a combination of both using the transgenic and/or knockout mouse approaches has provided useful insights into the molecular mechanisms of urothelial transformation and tumorigenesis. It is becoming increasingly clear that over-activation of the receptor tyrosine kinase (RTK) pathway, as exemplified by the constitutively activated Ha-ras oncogene, is both necessary and sufficient to initiate the low-grade, non-invasive urothelial carcinomas. Dosage of the mutated Ha-ras, but not concurrent inactivation of pro-senescence molecules p16Ink4a and p19Arf, dictates whether and when the low-grade urothelial carcinomas arise. Inactivation of both p53 and pRb, a prevailing paradigm previously proposed for muscle-invasive urothelial tumorigenesis, is found to be necessary but insufficient to initiate this urothelial carcinoma variant. Instead, downregulation in p53/pRb co-deficient urothelial cells of p107, a pRb family member, is associated with the genesis of the muscle-invasive bladder cancers. p53 deficiency also seems to be capable of cooperating with that of PTEN in eliciting invasive urothelial carcinomas. The genetically engineered mice have improved the molecular definition of the divergent pathways of urothelial tumorigenesis and progression, helped delineate the intricate crosstalk among different genetic alterations within a urothelium-specific context, identified new prognostic markers and novel therapeutic targets potentially applicable for clinical intervention, and provided in vivo platforms for testing preventive strategies of bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.